GeneDx, Prognos announce partnership to help rare disease patients

GeneDx and Prognos Health announced a strategic partnership to shorten the treatment odyssey for rare disease patients via real world data. The partnership offers life science companies a comprehensive de-identified dataset specific to rare disease to accelerate access to life saving therapies. Through this partnership, the Prognos Marketplace will integrate GeneDx’s de-identified rare disease data, including regularly updated data as GeneDx continues to add new genomic and health information retrieved through its whole genome and whole exome sequencing tests. Biopharma companies who work with Prognos will then be automatically alerted about clinicians who have newly diagnosed patients and may benefit from therapies that have been approved by the U.S. Food and Drug Administration.